The short answer: Most people notice less hunger within the first few weeks, but the scale moves slowly at first because the starting dose is only a first step. In the largest Zepbound (tirzepatide) trial, average weight loss reached roughly 15% to 22% of body weight at 72 weeks, depending on the dose, and it
Bottom Line In a 42-week, placebo-controlled Phase 2 trial of 485 adults, a once-weekly injection called petrelintide produced average weight loss of up to about 10% (up to 10.2% when everyone assigned to the drug is counted, up to 10.7% in people while they stayed on it), versus about 1.4% to 1.7% with placebo. It
A new weekly amylin drug shows about 10% weight loss in Phase 2 Petrelintide, a once-weekly amylin-based injection (a different hormone pathway from GLP-1), was tested in 485 adults for 42 weeks. Average weight loss was up to 10.2% when everyone assigned to the drug is counted (up to 10.7% in people while taking it),
Bottom Line Three independent 2026 surveys agree on the direction, even though they report different numbers: employer coverage of GLP-1 medications for weight loss is retrenching, not expanding, as the drugs’ cost collides with the size of the eligible population. Several large, recognizable employers have dropped or are dropping coverage this year. For patients whose
Bottom Line A large real-world study published in January 2026 found that people with type 2 diabetes on tirzepatide had a lower rate of newly diagnosed dementia over two years than people on semaglutide or on SGLT2 inhibitors, and that semaglutide also outperformed SGLT2 inhibitors. The differences are real and statistically significant, but this is
Employers are dropping GLP-1 weight-loss coverage Three 2026 surveys point the same way. A Business Group on Health survey found 60% of large employers now cover GLP-1s for weight loss, down from 72% in 2025, with Cigna and PwC already out and PepsiCo and Starbucks following in October. Employers Health says about 65% of its
